CAR-T cell therapy research
The multicentre CARTIFAN-1 phase II study in China reported responses to cilta-cel in previously treated multiple myeloma. This specialist treatment can cause serious adverse effects and requires strict eligibility assessment.
JCO · CARTIFAN-1 · 2023





